These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19399957)

  • 1. Translational cancer research in Europe.
    Fricker J
    Mol Oncol; 2007 Jun; 1(1):8-10. PubMed ID: 19399957
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab--mechanism of action and use in clinical practice.
    Hudis CA
    N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
    [No Abstract]   [Full Text] [Related]  

  • 3. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 4. [The requirements to clinicopathology about targeted therapy for breast cancer].
    Jiang ZF; Shen G
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
    [No Abstract]   [Full Text] [Related]  

  • 5. [Breast Cancer Conference. Trastuzumab and capecitabine in the treatment of advanced breast cancer. Milano, 6-7 June 2002].
    Longo F; Mansueto G
    Tumori; 2002; 88(5):A1-10. PubMed ID: 12489530
    [No Abstract]   [Full Text] [Related]  

  • 6. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 7. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 8. [Isolated effect of the monoclonal antibody trastuzumab (Herceptin) in a patient with local recurrence of breast carcinoma with HER-2 hyperexpression. ].
    Del Giglio A
    Rev Assoc Med Bras (1992); 2006; 52(4):202. PubMed ID: 16967134
    [No Abstract]   [Full Text] [Related]  

  • 9. Continuing trastuzumab beyond progression.
    Jahanzeb M
    J Clin Oncol; 2009 Apr; 27(12):1935-7. PubMed ID: 19289613
    [No Abstract]   [Full Text] [Related]  

  • 10. "Build quality in"--HER2 testing in the real world.
    Zujewski JA
    J Natl Cancer Inst; 2002 Jun; 94(11):788-9. PubMed ID: 12048261
    [No Abstract]   [Full Text] [Related]  

  • 11. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
    Slamon DJ
    Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
    [No Abstract]   [Full Text] [Related]  

  • 12. Trastuzumab beyond disease progression: case closed?
    Valabrega G; Aglietta M; Montemurro F
    J Clin Oncol; 2009 Sep; 27(27):e121-2; author reply e124-5. PubMed ID: 19687323
    [No Abstract]   [Full Text] [Related]  

  • 13. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab treatment beyond brain progression in HER2- positive metastatic breast cancer.
    Kilickap S; Arslan C
    Ann Oncol; 2009 Jan; 20(1):192. PubMed ID: 19172706
    [No Abstract]   [Full Text] [Related]  

  • 15. Perspective of trastuzumab treatment.
    Iwata H
    Breast Cancer; 2007; 14(2):150-5. PubMed ID: 17485899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of HER2 testing in breast cancer].
    Ni YB; Yang WJ; Bu H; Zheng H
    Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):76-8. PubMed ID: 21426800
    [No Abstract]   [Full Text] [Related]  

  • 17. Trastuzumab-based combination therapy for breast cancer.
    Montemurro F; Valabrega G; Aglietta M
    Expert Opin Pharmacother; 2004 Jan; 5(1):81-96. PubMed ID: 14680438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody therapy for breast cancer: herceptin.
    Finn RS; Slamon DJ
    Cancer Chemother Biol Response Modif; 2003; 21():223-33. PubMed ID: 15338747
    [No Abstract]   [Full Text] [Related]  

  • 19. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
    Liao C; Yin F; Huang P; Cao Y; Gao F
    Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
    [No Abstract]   [Full Text] [Related]  

  • 20. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.